Unknown

Dataset Information

0

Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization.


ABSTRACT: Mobilization of hematopoietic stem and progenitor cells (HSPCs) from bone marrow into peripheral blood by the cytokine granulocyte colony-stimulating factor (G-CSF) has become the preferred source of HSPCs for stem cell transplants. However, G-CSF fails to mobilize sufficient numbers of stem cells in up to 10% of donors, precluding autologous transplantation in those donors or substantially delaying transplant recovery time. Consequently, new regimens are needed to increase the number of stem cells in peripheral blood upon mobilization. Using a forward genetic approach in mice, we mapped the gene encoding the epidermal growth factor receptor (Egfr) to a genetic region modifying G-CSF-mediated HSPC mobilization. Amounts of EGFR in HSPCs inversely correlated with the cells' ability to be mobilized by G-CSF, implying a negative role for EGFR signaling in mobilization. In combination with G-CSF treatment, genetic reduction of EGFR activity in HSPCs (in waved-2 mutant mice) or treatment with the EGFR inhibitor erlotinib increased mobilization. Increased mobilization due to suppression of EGFR activity correlated with reduced activity of cell division control protein-42 (Cdc42), and genetic Cdc42 deficiency in vivo also enhanced G-CSF-induced mobilization. Our findings reveal a previously unknown signaling pathway regulating stem cell mobilization and provide a new pharmacological approach for improving HSPC mobilization and thereby transplantation outcomes.

SUBMITTER: Ryan MA 

PROVIDER: S-EPMC4464748 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


Mobilization of hematopoietic stem and progenitor cells (HSPCs) from bone marrow into peripheral blood by the cytokine granulocyte colony-stimulating factor (G-CSF) has become the preferred source of HSPCs for stem cell transplants. However, G-CSF fails to mobilize sufficient numbers of stem cells in up to 10% of donors, precluding autologous transplantation in those donors or substantially delaying transplant recovery time. Consequently, new regimens are needed to increase the number of stem ce  ...[more]

Similar Datasets

| S-EPMC5622863 | biostudies-literature
| S-EPMC3915091 | biostudies-literature
2007-08-09 | GSE7400 | GEO
| S-EPMC6361095 | biostudies-literature
| S-EPMC2581978 | biostudies-literature
| S-EPMC9530850 | biostudies-literature
| S-EPMC7132876 | biostudies-literature
| S-EPMC7016966 | biostudies-literature
| S-EPMC6373754 | biostudies-literature
| S-EPMC6119158 | biostudies-literature